Selexipag

Active substance
Selexipag
Domain
Lung diseases
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Other lung
Extended indication
Pulmonale arteriële hypertensie (PAH) WHO-klasse II–III bij volwassenen als monotherapie of als combinatietherapie met een endothelinereceptorantagonist (ERA) en/of een fosfodiësteraseremmer (PDE-5-remmer).

1. Product

Proprietary name
Uptravi
Manufacturer
Janssen
Mechanism of action
Receptor agonist
Route of administration
Intravenous
Additional comments
selectieve prostacycline IP-receptoragonist.

2. Registration

Registration route
Centralised (EMA)
Type of trajectory
Normal trajectory
Particularity
New therapeutical formulation
Orphan drug
Yes
Registration phase
No registration expected
Additional comments
Fabrikant geeft aan dat de intraveneuze vorm enkel in de Verenigde Staten op de markt zal komen. Op dit moment in tabletvorm goedgekeurd.

3. Therapeutic value

Current treatment options
Keuze op basis van vasoreactiviteit, risicoprognose en aangetoonde werkzaamheid per middel, bijvoorbeeld: Endothelinereceptor-antagonisten, Guanylaatcyclase-stimulator, PDE-5-remmers, Prostacycline-analogen, Prostacycline IP-receptor-agonisten.
Therapeutic value
No judgement
Duration of treatment
Not found

4. Expected patient volume per year

Additional comments
De geschatte prevalentie van PAH is 15-52 per 1.000.000.

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

There is currently nothing known about indication extensions.

9. Other information

There is currently no futher information available.